Stay updated on Pralsetinib in RET+ Cancer Clinical Trial
Sign up to get notified when there's something new on the Pralsetinib in RET+ Cancer Clinical Trial page.

Latest updates to the Pralsetinib in RET+ Cancer Clinical Trial page
- Check5 days agoChange DetectedDifference0.1%
- Check12 days agoChange DetectedThe expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.SummaryDifference0.3%
- Check20 days agoChange DetectedThe web page has been updated from version 2.16.2 to version 2.16.3.SummaryDifference0.0%
- Check27 days agoChange DetectedThe web page has been updated to reflect a new study with 71 locations, including several new sites in the United States and China, and the results have been posted. Additionally, the maximum tolerated dose and recommended phase 2 dose of pralsetinib have been defined, along with various metrics related to participant responses and adverse events.SummaryDifference100%
- Check34 days agoChange DetectedThe web page has been updated to reflect the upcoming modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, along with an invitation for API users to provide input. Additionally, the revision number has been updated from v2.16.0 to v2.16.1.SummaryDifference1%
- Check41 days agoChange DetectedThe page has been updated to include new studies on Pralsetinib for RET-altered thyroid cancer and RET fusion-positive non-small-cell lung cancer, while previous versions of these studies have been removed. Additionally, the page revision has been updated from v2.15.2 to v2.16.0.SummaryDifference8%
Stay in the know with updates to Pralsetinib in RET+ Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pralsetinib in RET+ Cancer Clinical Trial page.